Analysts Set Indivior PLC (NASDAQ:INDV) Price Target at $32.71

Shares of Indivior PLC (NASDAQ:INDV) have received an average recommendation of “Buy” from the nine analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $32.7143.

Several equities research analysts recently commented on INDV shares. Morgan Stanley reaffirmed an “overweight” rating and set a $36.00 price objective on shares of Indivior in a research report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Indivior in a report on Friday, October 31st. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 3rd. Northland Securities set a $40.00 price objective on shares of Indivior in a research report on Friday, October 31st. Finally, Piper Sandler restated an “overweight” rating and issued a $41.00 target price (up previously from $27.00) on shares of Indivior in a report on Friday, October 31st.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Indivior by 16.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock valued at $71,000 after purchasing an additional 666 shares during the period. CWM LLC purchased a new position in shares of Indivior in the third quarter worth approximately $25,000. Quarry LP bought a new stake in Indivior during the third quarter valued at approximately $26,000. Raymond James Financial Inc. purchased a new stake in Indivior during the second quarter valued at approximately $26,000. Finally, Campbell & CO Investment Adviser LLC raised its position in Indivior by 3.5% in the third quarter. Campbell & CO Investment Adviser LLC now owns 53,782 shares of the company’s stock worth $1,297,000 after acquiring an additional 1,834 shares during the period. Institutional investors own 60.33% of the company’s stock.

Indivior Stock Performance

Shares of NASDAQ:INDV opened at $35.21 on Friday. The business has a fifty day moving average price of $30.95 and a 200-day moving average price of $23.71. Indivior has a 1-year low of $7.62 and a 1-year high of $38.00.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.34. The company had revenue of $314.00 million during the quarter, compared to analyst estimates of $257.66 million. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%. As a group, equities analysts anticipate that Indivior will post 1.22 EPS for the current fiscal year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.